3,647 result(s) found
Q4 Earnings: Tech Flexes Strong Growth
https://www.zacks.com/commentary/2219124/q4-earnings-tech-flexes-strong-growth?cid=CS-ZC-FT-earnings_trends-2219124
Jan 31, 2024 - Total earnings for Tech companies that have already reported results are up +19.3% from the same period last year on +6.6% higher revenues. Will the trend continue?
0
Q4 Earnings: Tech Flexes Strong Growth
https://www.zacks.com/commentary/2219125/q4-earnings-tech-flexes-strong-growth?cid=CS-ZC-FT-earnings_outlook-2219125
Jan 31, 2024 - Total earnings for Tech companies that have already reported results are up +19.3% from the same period last year on +6.6% higher revenues. Will the trend continue?
0
Leerink ups 2seventy to outperform, cites attractiveness as takeover target
https://seekingalpha.com/news/4060882-leerink-ups-2seventy-to-outperform-cites-attractiveness-as-takeover-target?source=feed_sector_healthcare
Jan 31, 2024 - Leerink has upgraded 2seventy bio (TSVT) to outperform, citing the company’s attractiveness as an acquisition target. “While a commercial company with flat reve
0
PGA Tour secures up to $3 billion from U.S. investors as LIV Golf merger hangs in the balance
https://www.cnbc.com/2024/01/31/pga-tour-secures-up-to-3-billion-us-investment-amid-liv-golf-merger.html
Jan 31, 2024 - Strategic Sports Group's investment in the PGA Tour comes as the professional golf organization's merger with the Saudi-backed LIV Golf is up in the air.
0
Ford (F) Gears Up for Q4 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2218959/ford-f-gears-up-for-q4-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2218959
Jan 31, 2024 - The Zacks Consensus Estimate for Ford's (F) fourth-quarter sales and earnings is pegged at $36.39 billion and 12 cents per share, respectively.
0
ITT (ITT) Is Up 0.57% in One Week: What You Should Know
https://www.zacks.com/stock/news/2218965/itt-itt-is-up-0-57-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2218965
Jan 31, 2024 - Does ITT (ITT) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test
https://www.zacks.com/stock/news/2218936/bd-s-bdx-tie-up-to-offer-ai-based-digital-system-for-pap-test?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218936
Jan 31, 2024 - BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.
0
OTIS Q4 Earnings & Sales Top, New Equipment Orders Up 3%
https://www.zacks.com/stock/news/2218933/otis-q4-earnings-sales-top-new-equipment-orders-up-3?cid=CS-ZC-FT-analyst_blog|earnings_article-2218933
Jan 31, 2024 - Solid operational improvement, a lower share count and an effective tax rate improvement boost OTIS Q4 earnings.
0
NVR Q4 Earnings Beat, Homebuilding Revenues Lag, Orders Up 25%
https://www.zacks.com/stock/news/2218931/nvr-q4-earnings-beat-homebuilding-revenues-lag-orders-up-25?cid=CS-ZC-FT-analyst_blog|earnings_article-2218931
Jan 31, 2024 - NVR's fourth-quarter 2023 results are hurt by higher rates during the period compared to a year ago. Yet, improved demand trends led to higher orders.
0
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0